AbGeneron’s main scope is the research and development of novel antibody diagnostics and biopharmaceuticals (mAbs). Our aim is to discover, optimise and produce novel and biosimilar antibody and protein medicines and diagnostics, combining recombinant DNA technology, structure based design with the use of AI and protein engineering methods.
Our business scope is to discover and develop fully certified novel and biosimilar antibody molecules for the pharmaceutical and diagnostics industries employing state of the art and innovative scientific processes thus and aiming in both quality and cost efficiency in biopharmaceutical development, an area already in the frontline of pharma innovation.
- To Develop original and proprietary human and other species antibody libraries, for use in the discovery of novel diagnostics and biopharmaceuticals
- Establish a centre of excellence for the discovery and development of antibodies and other proteins, like insulin, with clinical and diagnostic merit.
- Establish a leading market presence in Greece in biosimilar processing and manufacturing.
- Development of the next generation of antibody medicines.